Boston, MA -- (ReleaseWire) -- 04/18/2014 -- The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
View Full Report Details and Table of Contents
This report contains a comprehensive listing of all asset purchase deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals. The chapter includes numerous case studies to enable understanding of both pure asset purchase deals and multicomponent deals where asset purchase forms a part.
Chapter 4 provides a review of the leading asset purchase deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Companies Mentioned in this Report: Abbott, Actavis, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Endo, Forest, Fresenius, Galderma, Gilead Sciences, GlaxoSmithKline, Grifols, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Lundbeck, Menarini, Merck & Co, Merck KGaA, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Ranbaxy, Roche, Sanofi, Servier, Shionogi, Shire, Stada, Takeda, Teva, UCB view, Valeant, Warner Chilcott
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Diagnostics Partnering Terms and Agreements
- Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
- Personalized Medicine in Oncology Partnering Terms and Agreements
- Personalized Medicine Partnering Terms and Agreements
- Drug Delivery Partnering Terms and Agreements
- Companion Diagnostics Partnering Terms & Agreements